Roche Announces Outcomes for EMBARK Study of Elevidys in Duchenne Muscular Dystrophy
2023-10-31 · Chugai Pharmaceutical · original chugai-pharm.co.jp ↗
TOKYO, October 31, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on October 30 (local time) regarding outcomes for EMBARK study in Duchenne muscular dystrophy (DMD) of microdystrophin gene therapy, Elevidys TM (Generic name: delandistrogene moxeparvovec, Development code: SRP-9001). Please refer to the link below for details of the press release: Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints https://www.roche.com/media/releases/med-cor-2023-10-30
The release as fetched from its publisher. chugai-pharm.co.jp ↗